TrialClinical pharmacology in drug development2026

A First-in-Japanese Phase 1, Double-Blind, Placebo-Controlled, Parallel-Cohort Study of Sefaxersen, an Antisense Oligonucleotide Targeting Complement Factor B, in Healthy Participants.

Takakazu Sato et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.